More on VRXA
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $1.86 |
|
|||
| Open | $1.88 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $1.95 | ||||
| Day Low | $1.85 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 25,686 | ||||
- Veraxa Biotech AG (VRXA) files for 25M share offering by selling stockholders
- VERAXA Biotech files first BiTAC patent applications, portfolio tops 50
- VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates
- VERAXA Biotech advances VXA-222 bispecific ADC program with OmniAb
- VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
- Veraxa Biotech shareholders approve all EGM resolutions with 99.94% vote
- VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth
- Form 6-K Veraxa Biotech AG For: Jul 23
- Veraxa Biotech names Christoph Erkel as chief scientific officer
- VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio
Entities mentioned with VRXA
- Twitter | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Definitive Agreement | View Related Stories »
- SPAC | View Related Stories »
- Cantor Fitzgerald | View Related Stories »
- IPO | View Related Stories »
- Show More...
